Aminobiphosphonate
PreclinicalSmall molecule
Aminobiphosphonate is one of 15 small molecule programs targeting T Cells. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in T Cells
#DrugCompanyPhaseTrials
1Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Fludara
SanofiPhase 2
Quercetin
MMayo Clinic
Phase 3
Keytruda
Merck & Co.Phase 1
CD19 CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Phase 2
CAR T Cells
CChongqing Precision Biotech Co., Ltd
Phase 2
Treanda
AAzurity Pharmaceuticals
Phase 1
Cyclophosphamide,fludarabine
HHebei Senlang Biotechnology Inc., Ltd.
Phase 1
CDX-1140
CCelldex Therapeutics
Phase 1
Ic9-CAR.B7-H3 T Cells
UUNC Lineberger Comprehensive Cancer Center
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aminobiphosphonate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAmsterdam UMC, location VUmc